Budecort Inhaler
Budesonide
200mcg
Cipla Ltd.
| Pack size | 1's |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 630.78 NPR |
Indications
Budecort Inhaler is used for:
Asthma, COPD.
Adult Dose
Inhalation
Asthma
Adult: As metered-dose aerosol: 400 mcg daily in 2 divided doses, increased up to 1.6 mg daily in severe cases. Maintenance: 200-400 mcg daily.
As dry powd inhaler: 200-800 mcg daily in single dose or in 2 divided doses. Max: 800 mcg bid.
As nebuliser soln: Severe asthma: 1-2 mg bid. Maintenance dose: 0.5-1 mg bid.
Child Dose
Inhalation
Asthma
Child: 2-12 yr As metered-dose aerosol: 200-800 mcg daily in divided doses.
5-12 yr As dry powd inhaler: 200-800 mcg daily in 2 divided doses.
3 mth to 12 yr As nebuliser soln: Initially, 0.5-1 mg bid.
Maintenance dose: 0.25-0.5 mg bid.
Inhalation
Croup
Child: As nebuliser soln: 2 mg as a single dose or as 2 doses of 1 mg w/ 30 min interval, may be repeated 12 hrly for a max of 36 hr or until clinical improvement is observed.
Renal Dose
Administration
Contra Indications
Hypersensitivity to any of the ingredients of this preparation.
Precautions
Active or doubtfully quiescent tuberculosis, paradoxical bronchospasm; untreated fungal, bacterial, or systemic viral infections, or ocular herpes simplex infection.
Lactation: Drug enters breast milk; use only if benefits greatly outweigh risks
Pregnancy-Lactation
Interactions
Increased systemic exposure w/ potent CYP3A4 inhibitors (e.g. ketoconazole). Decreased systemic exposure w/ CYP3A4 inducers (e.g. carbamazepine).
Adverse Effects
Side effects of Budesonide :
>10%
Respiratory infection (34-38%),Rhinitis (7-12%),Otitis media (1-12%)
1-10%
Nasopharyngitis (10%),Nasal congestion (3%),Pharyngitis (3%),Allergic rhinitis (2%),Viral gastroenteritis (2%),Viral upper respiratory tract infection (2%),Oral candidiasis (1%)
Mechanism of Action
Budesonide controls the rate of protein synthesis, depresses the migration of polymorphonuclear leukocytes, fibroblasts, reverses capillary permeability and lysosomal stabilisation at the cellular level to prevent or control inflammation.
Note
Budecort 200mcg Inhaler manufactured by Cipla Ltd.. Its generic name is Budesonide. Budecort is availble in Nepal.
Farmaco Nepal drug index information on Budecort Inhaler is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.